NCT07502521CompletedPhase 2
Dexrazoxane to Protect Against Hemorrhagic STEMI
Dexrazoxane for the Reduction of Haemorrhagic Myocardial Infarction in STEMI: A Double-Blind, Placebo-Controlled, Sequential-Cohort Phase IIa Trial
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
This Phase Ila trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 26 Mar 2026
- Start date
- 30 Aug 2025
- Primary completion date
- 15 Feb 2026
- Lead sponsor
- Rohan Dharmakumar
- Diseases
- Coronary artery disease
- NCT number
- NCT07502521
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 50
- From 30 Aug 2025 to the primary completion date, 15 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current anthracycline chemotherapy or active chest radiation (per patient/chart).
- Concurrent trials: investigational drug or device use within 90 days.
Other illness
- History of PCI or CABG within 1 year
- On iron chelation now or documented iron-storage disease (hemochromatosis/thalassemia).
- Any clinically significant condition identified that would preclude safe peri-procedural administration of Dexrazoxane or completion of core protocol procedures.
Lab values
- Known pre-existing LVEF \<40% from recent records
Other
- Known dialysis/ESRD
- Known pregnancy or breastfeeding (history or clearly documented)
Who the study is looking for
- Adult (18 - 79 years).
- First STEMI (EMS/ER ECG ST-elevation) with primary PCI planned.
- Consent pathway available: Patient consent, Legally Acceptable Representative (LAR)
- CMR likely be feasible (no known MRI-unsafe implant or absolute MRI prohibition)
Age in the registry: 18 years to 79 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Synergy Cardiovascular Research Center Coordinator of this site? Confirm its status | Rajkot | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.